Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer
Key Highlights
- ➤REALworld: AML launches to build pediatric AML evidence for future clinical trials
- ➤Blood Cancer United and Rally Foundation co-founded the patient-centered initiative
- ➤Tempus (TEM) provides Olivia health technology for participating families
- ➤PedAL has screened more than 660 children at over 100 medical centers worldwide
- ➤PedAL currently evaluates venetoclax and ziftomenib treatment arms
Expert Statements
Gwen Nichols, M.D., Chief medical officer of Blood Cancer United
“For children with rare diseases like AML, time matters”
Gwen Nichols, M.D., Chief medical officer of Blood Cancer United
“Because patient populations are small, clinical trials can be difficult to conduct, and research can move more slowly than families can afford to wait.”
Gwen Nichols, M.D., Chief medical officer of Blood Cancer United
“REALworld: AML gives children and families an opportunity to contribute directly to research while helping us build the evidence researchers need to design more efficient studies and advance better treatment options.”
Dean Crowe, Founder and CEO of Rally Foundation for Childhood Cancer Research
“Families confronting pediatric AML urgently need research approaches designed around the realities of rare childhood cancers.”
Dean Crowe, Founder and CEO of Rally Foundation for Childhood Cancer Research
“We are proud to have helped co-found REALworld: AML and support an initiative that puts families at the center of research.”
Dean Crowe, Founder and CEO of Rally Foundation for Childhood Cancer Research
“By building high-quality evidence from the experiences of children with AML, we have an opportunity to advance treatment development while creating a model that could ultimately benefit children facing other rare cancers.”
Chris Scotto DiVetta, SVP of Olivia at Tempus
“The promise of Olivia is to ensure every patient receives the full benefit of what medicine offers, while also accelerating scientific discovery to improve those benefits.”
Chris Scotto DiVetta, SVP of Olivia at Tempus
“Olivia puts meaningful health and educational resources directly into the hands of families, while creating new opportunities for them to play an active role in advancing pediatric AML research.”
Chris Scotto DiVetta, SVP of Olivia at Tempus
“We’re thrilled to be part of the Dare to Dream Project and contribute to an initiative that has the potential to make a meaningful difference for children and families.”
Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer PR Newswire
Dare to Dream Project will build a real-world data set that can inform pediatric AML research and future clinical trials while helping families better understand their health information
Get started
Create a free account to read the full story.